Weil C, et al. - The goals of this study were to characterize patients initiating ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin (OPrD±RBV) and assess sustained virological response (SVR) for hepatitis C. Researchers noticed high SVR rates in various patient subgroups and comorbidities after a first year of provision of OPrD±RBV with good adherence.

Methods

• Researchers performed a retrospective cohort study using the database of Maccabi Healthcare Services (MHS), a 2-million-member health plan in Israel.
• Adults who initiated OPrD±RBV through December 2015 per health basket criteria were included.
• They used a gap in medication fills (>14 days between a fill's run-out and the next fill) and estimated adherence.
• They defined SVR by the viral tests at least 12 weeks post-treatment.

Results

• 403 patients (56.3% male) were included; mean age was 60.7 years (SD 11.0).
• In this study, 71.0% patients were naïve to prior HCV treatment and 95.6% were treated with a 12-week regimen.
• The regimen was completed by a total of 348 patients (86.4%) in the usual time frame (highly adherent), however, 8.2% completed the regimen with a gap, and 4.7% purchased less than the recommended dose.
• Overall and among highly adherent patients, SVR rates were 395/403 (98.0%; 95%CI 96.1-99.1%) and 346/348 (99.4%; 95%CI 97.9-99.9%), respectively.
• SVR rates of 194/196 (fibrosis F3) and 170/176 (cirrhosis) were evident in GT1b patients on 12-week regimens.